Harry Welten

Harry Welten currently works at BioSupport AG, as Director, Kanyos Bio, Inc., as Director, Affimed NV, as Chief Financial Officer from 2023, Horizon Therapeutics Switzerland GmbH, as Member-Management Board, Fondation De l'Hôpital Barrie Memorial, as Member-Foundation Council, HBM Fondation, as Member-Foundation Council, and Affimed GmbH, as Member-Supervisory Board.
Mr. Welten also formerly worked at Novaremed AG, as Chairman from 2018 to 2020, Proteomedix AG, as Chairman, UBS Securities LLC, as Director, Kuros Biosurgery Holding AG, as Director, European Medical Solutions, as Independent Director, Synosia Therapeutics, Inc., as Director, BiognoSYS AG, as Director, Proteomedix AG, as Director, Anokion SA, as Director, Kuros Biosciences Ltd., as Director in 2018, Kuros Biosciences AG, as Director, Virometix AG, as Director, Synosia Therapeutics AG, as Member-Management Board, Cytos Biotechnology AG, as Chief Financial Officer & Executive Vice President from 2011 to 2012, and Arpida AG, as Chief Financial Officer & Senior Vice President in 2009.
Mr. Welten received his undergraduate degree and Masters Business Admin degree from The Trustees of Columbia University in The City of New York.